Supporting Regulatory Approval of Breakthrough Alzheimer’s Therapy

Background

Perceptive was selected by one of the world’s leading pharmaceutical companies to provide clinical trial imaging services for a phase 3 study assessing the safety, tolerability, and efficacy of a novel, amyloid plaque-targeting therapy for Early Symptomatic Alzheimer’s Disease (AD). The compound was designated a breakthrough therapy by the FDA, meaning that we would have to meet the operational, regulatory, medical, and scientific demands to help the sponsor achieve their accelerated development timelines.